AARD: Aardvark Therapeutics, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
71 institutions reported holding $55.01M of Aardvark Therapeutics, Inc. on Form 13F (79 the quarter before). 18 opened a new position and 24 sold out. Shares held by institutions: -6%.
| Largest holders | Shares | Value |
|---|---|---|
| Decheng Capital LLC | 3,917,299 | $22.56M |
| CITADEL ADVISORS LLC | 1,283,166 | $7.39M |
| Laurion Capital Management LP | 1,034,459 | $5.96M |
| VANGUARD CAPITAL MANAGEMENT LLC | 562,877 | $3.24M |
| AQR CAPITAL MANAGEMENT LLC | 480,249 | $2.77M |
| EcoR1 Capital, LLC | 396,194 | $2.28M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 300,000 | $1.73M |
| CANTOR FITZGERALD, L. P. | 233,164 | $1.34M |
| BlackRock, Inc. | 187,045 | $1.08M |
| GEODE CAPITAL MANAGEMENT, LLC | 149,844 | $864K |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.